Recruiting now—All ages

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Sponsor: Wake Forest University Health Sciences · NCT06958107 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Sarcoma

What it tests

Non-Metastatic and Resectableother
Metastatic and Un-resectableother
No evidence of disease, under surveillanceother
ALT or WDLSother

Where it's running2 sites

Levine Cancer Institute
Charlotte, North Carolina 28204
Recruiting now
- Meg Lattanze(contact)980-442-4239 [email protected]
- Johann Hsu, MD(principal investigator)
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina 27103
Recruiting now
- Shailaja Raj(contact)336-716-7970 [email protected]

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
2. All ages allowed
3. Suspected or confirmed disease (must meet one of the criteria below):

   1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)

      OR
   2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery

      OR
   3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:

      * Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
      * Metastatic or unresectable sarcoma, with planned or currently receiving therapy
      * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy

Exclusion Criteria:

* none

Updated 2026-01-22 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.